Yale University’s Cardiovascular Research Group (YCRG) and medical device CRO genae associates nv, have announced a collaboration and co-marketing agreement for cardiovascular devices.
New Haven, Connecticut-based YCRG and Belgium-based genae will formalize platforms to facilitate the cross-marketing and referral of services to each other, as well as to liase with regulatory and governmental bodies and co-deploy staff, facilities and other resources where necessary
YCRG and genae will also increase market reach by sharing and sub-contracting monitoring, regulatory, safety, core laboratory, data management and statistical analysis services.
YCRG Director Dr. Alexandra Lansky, who has served as the principal investigator for numerous trials investigating novel cardiovascular devices and adjunctive pharmacology, said, "This unique ARO/CRO collaboration takes advantage of the opportunities of sponsored clinical trials to advance scientific understanding and to promote a broad application of evidence-based medicine that will ultimately benefit patients.
“The growing demand for high-quality but cost-conscious clinical research faces technological, economic and regulatory change," Dr. Lansky added.